Welireg, a rare anticancer drug for a small number of patients, can now be prescribed in general hospitals in Korea.

According to industry sources on the 17th, MSD Korea’s oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, ‘Welireg (belzutifan) passed the drug committees (DCs) of various medical centers in Korea including the National Cancer Center, Samsung Medical Center, and Asan Medical Center.

Welireg was designated an orphan drug in Korea for the treatment of Von Hippel-Lindau disease in January last year, then formally approved in May of the same year.

Specifically, the drug is indicated for the treatment of adult patients with VHL disease who require thera